ストックスクリーナーアプリを入手
118.53
2.66%
-3.24
前日終値:
$121.77
開ける：
$122.97
24時間の取引高:
435.19K
Relative Volume:
0.49
時価総額：
$5.78B
収益：
$338.46M
当期純損益:
$-310.96M
株価収益率:
-18.15
EPS:
-6.53
ネットキャッシュフロー:
$-132.82M
1週間 パフォーマンス:
-6.51%
1か月 パフォーマンス:
-6.23%
6か月 パフォーマンス:
+32.23%
1年 パフォーマンス:
+48.53%
1日の値動き範囲:
$118.00
$122.97
1週間の範囲:
$117.60
$130.20
52週間の値動き範囲:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
名前
Axsome Therapeutics Inc
セクター
電話
(212) 332-3241
住所
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
118.53 | 5.78B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-12-31 | 繰り返されました | Mizuho | Outperform |
| 2024-09-03 | 開始されました | Wells Fargo | Overweight |
| 2024-08-06 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-04-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2024-01-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-08-08 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 開始されました | Piper Sandler | Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2022-09-07 | 再開されました | Mizuho | Buy |
| 2021-08-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 開始されました | Berenberg | Buy |
| 2021-01-08 | 開始されました | Jefferies | Buy |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-09-29 | 開始されました | BofA Securities | Underperform |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-14 | 開始されました | Cowen | Outperform |
| 2019-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-16 | 繰り返されました | Guggenheim | Buy |
| 2019-10-16 | 開始されました | Guggenheim | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-28 | 開始されました | SunTrust | Buy |
| 2019-05-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-08 | 開始されました | SVB Leerink | Outperform |
| 2019-03-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2015-12-15 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Axsome Therapeutics Inc (AXSM) 最新ニュース
Cibc World Markets Corp Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
6,119 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Fox Run Management L.L.C. - MarketBeat
Mizuho Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $216.00 - MarketBeat
Axsome succeeds in late-stage trial for ADHD therapy - MSN
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views - Benzinga
Medical Properties Trust : Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - Marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 4.9%Should You Sell? - MarketBeat
Bayer gains cancer drug from China’s Puhe; Axsome gets mixed ADHD data - BioPharma Dive
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Mizuho Securities Adjusts Axsome Therapeutics Price Target to $216 From $212, Maintains Outperform Rating - Marketscreener.com
Axsome’s Sunosi succeeds in Phase III ADHD trial - Yahoo Finance
13,460 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by HighTower Advisors LLC - MarketBeat
Axsome’s latest win comes in ADHD, Opthea seeks path after AMD miss, and more: Clinical Report - BioCentury
Why Pharma and Biotech Stocks Got Thrashed on Tuesday - The Motley Fool
Axsome’s Scores In ADHD, But Differentiation In Generic-Heavy Market Unclear - News & Insights
Axsome reports Phase 3 win for Sunosi in adults with ADHD, with a high-dose caveat - Endpoints News
Axsome Therapeutics’ Promising Phase III FOCUS Trial Results Boost Buy Rating - TipRanks
Axsome shares fall after ADHD trial results By Investing.com - Investing.com UK
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal - Benzinga
Axsome stock rises on trial win for ADHD drug (AXSM:NASDAQ) - Seeking Alpha
Axsome Therapeutics' ADHD Trial Achieves Primary, Key Secondary Endpoints - Nasdaq
New ADHD treatment shows promise in phase 3 trial - Investing.com
Axsome Therapeutics' ADHD drug meets main goal in late-stage study - TradingView
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint - The Manila Times
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention - Bluefield Daily Telegraph
Major Breakthrough: Axsome's ADHD Drug Shows 45% Symptom Reduction in Phase 3 Trial - StockTitan
Intech Investment Management LLC Purchases 5,087 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Strong Growth and Positive Outlook for Axsome Therapeutics’ Auvelity Drives Buy Rating - TipRanks
Royce & Associates LP Acquires 14,500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Privium Fund Management B.V. Has $5.27 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Raymond James Financial Inc. Purchases Shares of 174,586 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome: The Alzheimer’s Agitation Program For AXS-05 (NASDAQ:AXSM) - Seeking Alpha
Charles Schwab Investment Management Inc. Grows Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Takes $6.22 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Great Lakes Advisors LLC Sells 3,220 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
How To Trade (AXSM) - Stock Traders Daily
Axsome Therapeutics’ AXS-12: A Promising Asset in Narcolepsy Treatment Driving Buy Rating - TipRanks
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock rises 5.8% this past week - Simply Wall St
Q1 EPS Forecast for Axsome Therapeutics Lifted by Analyst - MarketBeat
Equities Analysts Issue Forecasts for AXSM FY2027 Earnings - MarketBeat
Axsome Therapeutics Inc (AXSM) 財務データ
収益
当期純利益
現金流量
EPS
Axsome Therapeutics Inc (AXSM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Option Exercise |
3.50 |
3,000 |
10,500 |
45,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 13 '25 |
Sale |
129.86 |
12,000 |
1,558,320 |
42,187 |
| Pizzie Nick | Chief Financial Officer |
Feb 14 '25 |
Sale |
131.07 |
3,000 |
393,210 |
42,187 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):